drugset
drugset / Trial / NCT03758456

HAL-MRE1 Subcutaneous Immunotherapy in Ragweed Allergic Patients First-in-human

NCT03758456 ↗

Phase 1 Completed 45 enrolled HAL Allergy
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The aim of this first-in-human phase I study is to assess the safety and tolerability of HAL-MRE1 subcutaneous immunotherapy in subjects suffering from ragweed pollen-induced allergic rhinitis/rhinoconjunctivitis with or without asthma. The study has 4 treatment groups: 1 placebo group and 3 groups treated with different doses of HAL-MRE1.

Timeline

Start
2018-11-21
Primary completion
2019-05-17
Completion
2019-05-17

Drugs

EvaluationDrugModalityDoseRoute
Subject HAL-MRE1 Protein / enzyme biologic 5000 unknown Subcutaneous
Subject HAL-MRE1 Protein / enzyme biologic 10000 unknown Subcutaneous
Subject HAL-MRE1 Protein / enzyme biologic 20000 unknown Subcutaneous

Indications

allergic rhinitis